Search

everythinglearnresearchcommunity

for

Search:↓

The current understanding of frontal fibrosing alopecia involves immune, genetic, hormonal factors, and possibly environmental triggers, but more research is needed for effective treatments.

Immunosuppressive and anti-TNF therapies in IBD patients can increase the risk of skin cancer and cause various skin issues.

New treatments for ichthyosis, like protein replacement and gene therapy, show promise and may become standard care.

Tumor suppressors help control inflammation in cancer and restoring their function could lead to new treatments.

The best treatment for Frontal Fibrosing Alopecia and Lichen Planopilaris combines oral and topical medications to reduce symptoms and stop hair loss.

Frontal Fibrosing Alopecia's cause is unclear, affects mainly postmenopausal women, and current treatments focus on stopping hair loss rather than regrowth.

High levels of ERK activity are key for tissue regeneration in spiny mice, and activating ERK can potentially redirect scar-forming healing towards regenerative healing in mammals.

Tofacitinib helped a woman regrow hair with no major side effects.

OR-101 shows promise for treating alopecia areata by improving hair growth.

Adults and adolescents with severe alopecia areata are willing to take significant health risks for a better chance of hair regrowth.

Tofacitinib regrew hair in a man with total hair loss but raised cytokine levels, needing more research on possible side effects.

Both individual and combined treatments of tofacitinib and corticosteroids can help regrow hair in moderate-to-severe alopecia areata, but ongoing treatment may be necessary.

Upadacitinib and narrowband UVB effectively treated a child's vitiligo and alopecia areata.

Patients with severe alopecia areata felt better and less anxious or depressed when treated with baricitinib compared to placebo.

Tofacitinib works better and is more tolerable for severe alopecia than conventional treatments and DPCP immunotherapy.

Finasteride helps female-pattern hair loss.

Tofacitinib is a potential alternative treatment for alopecia totalis, especially in patients with a shorter duration of the condition and more preserved hair follicles, but the overall response rate is low.

Higher granulysin levels in the blood are linked to more severe hair loss in alopecia areata patients, and these levels decrease after effective treatment.

Both vitiligo and alopecia areata involve an immune response triggered by stress and specific genes, with treatments targeting this pathway showing potential.

Natural products show promise for new hair loss treatments.

Increasing Treg cells in the skin does not cure hair loss from alopecia areata in mice.

Regrowing scalp hair improves quality of life and reduces anxiety and depression in severe alopecia areata patients.

Ruxolitinib effectively regrows hair in most patients with severe hair loss.

CXCL12 protein slows down hair growth through its receptor CXCR4. Blocking this can potentially increase hair growth.

Old drugs like finasteride and spironolactone are being successfully used for hair loss and skin conditions, and many other drugs show promise for new uses in dermatology.

Minoxidil is the only FDA-approved topical drug for treating male or female pattern hair loss, and other medications like finasteride and dutasteride can also increase hair growth.

The meeting highlighted the importance of genetic testing and multidisciplinary approaches in pediatric dermatology.

A gene variant increases the risk of a type of hair loss by affecting hair protein production.

Tofacitinib improved hair loss and skin symptoms in a patient after secukinumab caused hair loss.

Costunolide may have multiple health benefits, including promoting hair growth and protecting against cancer and diabetes, but more research is needed.